Stocky turns companies like ORIC Pharmaceuticals, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →ORIC Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how much money the company made or lost, helping investors understand if the business is improving.
More employee stock means existing shareholders own a smaller piece; companies do this to attract talent.
Shows the company adjusted how it rewards employees; shareholders approved the changes at annual meeting.
Shows quarterly performance and cash position, helping investors track progress over time.
Showed progress on a drug candidate in testing; positive trial data can make a biotech company more valuable.
Stocky reads ORIC Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
ORIC Pharmaceuticals, Inc.'s most recent tracked filing was a 10-Q on 3 Aug 2026: Reported Q2 2026 financial results on August 3.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.